| Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective. | |
| | |
MedLine Citation:
|
PMID: 22316275 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Objective: In the Medical Research Council Myeloma IX Study (MMIX), zoledronic acid (ZOL) 4 mg 3-4/week reduced the incidence of skeletal-related events (SREs), increased progression free survival (PFS), and prolonged overall survival (OS), compared with clodronic acid (CLO) 1600 mg daily, in 1970 patients with newly-diagnosed multiple myeloma (MM). Methods: An economic model was used to project PFS, OS, the incidence of SREs and adverse events and expected lifetime healthcare costs for patients with newly-diagnosed MM who are alternatively assumed to receive ZOL or CLO. The incremental cost-effectiveness ratio [ICER] of ZOL vs CLO was calculated as the ratio of the difference in cost to the difference in quality-adjusted life years (QALYs). Model inputs were based on results of MMIX and published sources. Results: Compared with CLO, treatment with ZOL increases QALYs by 0.30 at an additional cost of £1653, yielding an ICER of £5443 per QALY gained. If the threshold ICER is £20,000 per QALY, the estimated probability that ZOL is cost-effective is 90%. Limitations: The main limitation of this study is the lack of data on the effects of zoledronic acid on survival beyond the end of follow-up in the MMIX trial. However, cost-effectiveness was favourable even under the highly conservative scenario in which the timeframe of the model was limited to 5 years. Conclusions: Compared with clodronic acid, zoledronic acid represents a cost-effective treatment alternative in patients with multiple myeloma. |
| | |
Authors:
|
Thomas E Delea; Jason Rotter; Matthew Taylor; David Chandiwana; Manjinder Bains; Khalid El Ouagari; Satyin Kaura; Gareth J Morgan |
Related Documents
:
|
7284425 - Studies on cyclopropane fatty acid synthesis. correlation between the state of reductio... 15062875 - Characterization of xanthine oxidase inhibition by anacardic acids. 8037765 - Fatty acid hydroxylase of the fungus fusarium oxysporum is possibly a fused protein of ... 9662615 - Indole acetic acid and its metabolism in root nodules of a monocotyledonous tree roysto... 15033755 - The sesame seed oil constituent, sesamol, induces growth arrest and apoptosis of cancer... 16928615 - Effects of low molecular weight heparin on the frequencies of intradialytic arrhythmias... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-9 |
Journal Detail:
|
Title: Journal of medical economics Volume: - ISSN: 1941-837X ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9892255 Medline TA: J Med Econ Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
PAI (Policy Analysis Inc.) Brookline, MA , USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High Preoperative Plasma Neopterin Predicts Delirium After Cardiac Surgery in Older Adults.
Next Document: Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary sy...